A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014)

Trial Profile

A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Nilotinib (Primary) ; Cytarabine; Dexamethasone; Granulocyte colony-stimulating factors; Imatinib; Methotrexate; Methylprednisolone acetate; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Acronyms GRAALL-2014; GRAAPH2014
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 24 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top